Corvus Pharmaceuticals Stock Forecast, Price & News

Corvus Pharmaceuticals (NASDAQ:CRVS) Frequently Asked Questions

Is Corvus Pharmaceuticals a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corvus Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Corvus Pharmaceuticals stock.
View analyst ratings for Corvus Pharmaceuticals or view top-rated stocks.

How has Corvus Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Corvus Pharmaceuticals' stock was trading at $2.71 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CRVS shares have increased by 21.4% and is now trading at $3.29.
View which stocks have been most impacted by COVID-19.

Are investors shorting Corvus Pharmaceuticals?

Corvus Pharmaceuticals saw a decrease in short interest during the month of November. As of November 15th, there was short interest totaling 1,050,000 shares, a decrease of 42.9% from the October 31st total of 1,840,000 shares. Based on an average daily volume of 8,340,000 shares, the days-to-cover ratio is presently 0.1 days. Currently, 3.5% of the company's shares are sold short.
View Corvus Pharmaceuticals' Short Interest.

When is Corvus Pharmaceuticals' next earnings date?

Corvus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, March 24th 2022.
View our earnings forecast for Corvus Pharmaceuticals.

How were Corvus Pharmaceuticals' earnings last quarter?

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) issued its quarterly earnings data on Sunday, October, 31st. The company reported ($0.24) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($0.24).
View Corvus Pharmaceuticals' earnings history.

What price target have analysts set for CRVS?

4 brokerages have issued twelve-month price objectives for Corvus Pharmaceuticals' shares. Their forecasts range from $3.50 to $8.00. On average, they anticipate Corvus Pharmaceuticals' share price to reach $6.38 in the next twelve months. This suggests a possible upside of 93.8% from the stock's current price.
View analysts' price targets for Corvus Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Corvus Pharmaceuticals' key executives?

Corvus Pharmaceuticals' management team includes the following people:

• Richard A. Miller, Chairman, President & Chief Executive Officer
• Leiv Lea, Chief Financial Officer
• Suresh Mahabhashyam, Vice President-Clinical Development
• Joseph J. Buggy, Executive Vice President-Discovery Research
• William B. Jones, Senior Vice President-Pharmaceutical Development

What is Richard A. Miller, MD's approval rating as Corvus Pharmaceuticals' CEO?

4 employees have rated Corvus Pharmaceuticals CEO Richard A. Miller, MD on Glassdoor.com. Richard A. Miller, MD has an approval rating of 100% among Corvus Pharmaceuticals' employees. This puts Richard A. Miller, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Corvus Pharmaceuticals' key competitors?

Some companies that are related to Corvus Pharmaceuticals include Phathom Pharmaceuticals (PHAT), Amryt Pharma (AMYT), Eagle Pharmaceuticals (EGRX), Applied Molecular Transport (AMTI), Enochian Biosciences (ENOB), SIGA Technologies (SIGA), DiaMedica Therapeutics (DMCAF), Immuneering (IMRX), POINT Biopharma Global (PNT), Arbutus Biopharma (ABUS), Inventiva (IVA), ANI Pharmaceuticals (ANIP), Chimerix (CMRX), Veru (VERU) and PyroGenesis Canada (PYR).
View all of CRVS's competitors.

What other stocks do shareholders of Corvus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corvus Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Dynavax Technologies (DVAX), Vaxart (VXRT), Zosano Pharma (ZSAN), SCYNEXIS (SCYX), Miragen Therapeutics (MGEN), Aldeyra Therapeutics (ALDX) and Bionano Genomics (BNGO).

When did Corvus Pharmaceuticals IPO?

(CRVS) raised $75 million in an IPO on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Credit Suisse and Cowen and Company acted as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers.

What is Corvus Pharmaceuticals' stock symbol?

Corvus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRVS."

Who are Corvus Pharmaceuticals' major shareholders?

Corvus Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Tang Capital Management LLC (8.05%), VR Adviser LLC (7.36%), EcoR1 Capital LLC (4.47%), BVF Inc. IL (2.95%), Pura Vida Investments LLC (1.58%) and Renaissance Technologies LLC (1.32%). Company insiders that own Corvus Pharmaceuticals stock include Ecor1 Capital, Llc, Holdings A/S Novo, Orbimed Advisors Llc and Richard A Md Miller.
View institutional ownership trends for Corvus Pharmaceuticals.

Which major investors are selling Corvus Pharmaceuticals stock?

CRVS stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, EcoR1 Capital LLC, CHI Advisors LLC, Dimensional Fund Advisors LP, Two Sigma Investments LP, Telemetry Investments L.L.C., Renaissance Technologies LLC, and BlackRock Inc.. Company insiders that have sold Corvus Pharmaceuticals company stock in the last year include Ecor1 Capital, Llc, and Orbimed Advisors Llc.
View insider buying and selling activity for Corvus Pharmaceuticals or view top insider-selling stocks.

Which major investors are buying Corvus Pharmaceuticals stock?

CRVS stock was bought by a variety of institutional investors in the last quarter, including Tang Capital Management LLC, VR Adviser LLC, Pura Vida Investments LLC, Point72 Asset Management L.P., Artal Group S.A., Citadel Advisors LLC, Jane Street Group LLC, and MYDA Advisors LLC. Company insiders that have bought Corvus Pharmaceuticals stock in the last two years include Orbimed Advisors Llc, and Richard A Md Miller.
View insider buying and selling activity for Corvus Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Corvus Pharmaceuticals?

Shares of CRVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Corvus Pharmaceuticals' stock price today?

One share of CRVS stock can currently be purchased for approximately $3.29.

How much money does Corvus Pharmaceuticals make?

Corvus Pharmaceuticals has a market capitalization of $153.14 million. The company earns $-5.99 million in net income (profit) each year or $0.06 on an earnings per share basis.

How many employees does Corvus Pharmaceuticals have?

Corvus Pharmaceuticals employs 42 workers across the globe.

What is Corvus Pharmaceuticals' official website?

The official website for Corvus Pharmaceuticals is www.corvuspharma.com.

Where are Corvus Pharmaceuticals' headquarters?

Corvus Pharmaceuticals is headquartered at 863 Mitten Road Suite102, BURLINGAME CA, 94010.

How can I contact Corvus Pharmaceuticals?

Corvus Pharmaceuticals' mailing address is 863 Mitten Road Suite102, BURLINGAME CA, 94010. The company can be reached via phone at (650) 900-4520 or via email at [email protected].